Acute pelvic inflammatory disease: a clinical follow-up.

In: International journal of fertility · 1987 · vol. 32(3) , pp. 229–32 · PMID:2885288 · W202845128
article OA: closed CC0 ⤵ 4 in-corpus citations
View on OpenAlex View on PubMed
AI-generated summary by claude@2026-06, 2026-06-08

This study followed 182 women with acute pelvic inflammatory disease for up to 8 years and found increased infertility and ectopic pregnancy rates, with severity correlating to worse outcomes.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

One hundred eighty-two women were diagnosed by laparoscopy as having an initial episode of acute pelvic inflammatory disease (PID). The classification of PID was based on a modification of Westrom's criteria. Antibiotic treatment followed recommended protocols established by the Centers for Disease Control (CDC). Each year, the woman is contacted to complete a questionnaire detailing her reproductive history, presence of pelvic pain, and menstrual history, as well as other miscellaneous gynecologic history. The study covers a follow-up interval of six months to 8 years. The results are categorized according to the severity of the acute PID, as well as the time elapsed since the infection. A psychological investigation of post-PID pain was performed, and yielded accurate prediction of whether or not pain had been reported by a patient during the acute phase of the disease. Results indicate an increased incidence of involuntary sterility as the disease progresses in severity. The occurrence of ectopic pregnancy is increased for all stages of PID, but most particularly, following tubo-ovarian abscess. The long-term consequences of a single episode of acute PID are often severe.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (4)

Cited by (4)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK